3011 T3D2969 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 9th ed, p1160) 13292-46-1 5381226 C43H58N4O12 822.405120 White powder. 183°C 1400 mg/L (at 25°C) Oral. Well absorbed from gastrointestinal tract. Rifampin acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death. Primarily hepatic, rapidly deacetylated. Route of Elimination: Less than 30% of the dose is excreted in the urine as rifampin or metabolites. Half Life: 3.35 (+/- 0.66) hours LD50: 1570 mg/kg (Rat) (A308) 3, not classifiable as to its carcinogenicity to humans. (L135) For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections. Antibiotic resistance Chronic exposure may cause nausea and vomiting and unconsciousness Intensive support measures should be instituted and individual symptoms treated as they arise. Since nausea and vomiting are likely to be present, gastric lavage is probably preferable to induction of emesis. Following evacuation of the gastric contents, the instillation of activated charcoal slurry into the stomach may help absorb any remaining drug from the gastrointestinal tract. Antiemetic medication may be required to control severe nausea and vomiting. Active diuresis (with measured intake and output) will help promote excretion of the drug. Hemodialysis may be of value in some patients. (L1712) 2009-07-21T20:28:15Z 2014-12-24T20:25:54Z Rifampin C06688 28077 Rifampin DB01045 RFP true [H]C(=NN1CCN(C)CC1)C1=C(O)C2=C3C(O)=C(C)C4=C2C(=O)[C@](C)(O4)O\C([H])=C([H])/[C@]([H])(OC)[C@@]([H])(C)[C@@]([H])(OC(C)=O)[C@]([H])(C)[C@]([H])(O)[C@]([H])(C)[C@@]([H])(O)[C@@]([H])(C)C([H])=C([H])\C([H])=C(C)/C(O)=NC1=C3O C43H58N4O12 InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14-,22-13-,44-20-/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1 InChIKey=JQXXHWHPUNPDRT-XHVADFQNSA-N 822.9402 822.40512334 Exogenous Solid 2.7 HMDB15179 CHEMBL374478 10468813 <p>Klaus Jurgen, Joachim Seydel, &#8220;Combination preparations containing rifampicin and thioacetazon.&#8221; U.S. Patent US5104875, issued August, 1973.</p>